|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) VA Connecticut Healthcare System |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000278 |
Purpose
The purpose of this study is to evaluate disulfiram for cocaine-alcohol abuse.
| Condition | Intervention | Phase |
|
Alcohol-Related Disorders Cocaine-Related Disorders |
Drug: Disulfiram |
Phase II |
| Drug Information available for: | Disulfiram 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride Ethanol |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Disulfiram for Cocaine-Alcohol Abuse |
Eligibility
| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, Connecticut | |||||
| VA Connecticut Healthcare System | |||||
| New Haven, Connecticut, United States, 06519 | |||||
| National Institute on Drug Abuse (NIDA) |
| VA Connecticut Healthcare System |
| Principal Investigator: | Thomas R Kosten, M.D. | VA Connecticut Healthcare System |
More Information
| Study ID Numbers: | NIDA-09250-3, P50-09250-3 |
| First Received: | September 20, 1999 |
| Last Updated: | August 16, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000278 |
| Health Authority: | United States: Federal Government |
|
|
|
|